Table 1: Baseline characteristics of the included trials in this meta-analysis.

StudyPeginterferonRibavirinBaseline treatment historyHCV genotypeTreatment in weeksCountryPublication yearStudy type

Yenice et al. [5]α-2a 180 ug/week;
α-2b 1.5 ug/kg/week
800–1200 mg/dayNaïve124 or 48Turkey2006RCT
Di Bisceglie et al. [6]α-2a 180 ug/week;
α-2b 1.5 ug/kg/week
1000–1200 mg/dayNaïve112USA2007RCT
Scotto et al. [7]α-2a 180 ug/week;
α-2b 1.5 ug/kg/week
15 mg/kg/dayNonresponders1,2,3,448Italy2008RCT
McHutchison et al. [8]α-2a 180 ug/week;
α-2b 1.5 ug/kg/week
800–1400 mg/dayNaïve124 or 48IDEAL study team2009RCT
Rumi et al. [9]α-2a 180 ug/week;
α-2b 1.5 ug/kg/week
800–1200 mg/dayNaïve1,2,3,424 or 48Italy2010RCT
Ascione et al. [10]α-2a 180 ug/week;
α-2b 1.5 ug/kg/week
1000–1200 mg/dayNaïve1,2,3,424 or 48Italy2010RCT
Mach et al. [11]α-2a 180 ug/week;
α-2b 1.5 ug/kg/week
1000–1200 mg/dayNaïve1b48Poland2011RCT